- Previous Close
456.10 - Open
456.10 - Bid 427.00 x --
- Ask 427.90 x --
- Day's Range
424.00 - 456.10 - 52 Week Range
350.00 - 1,600.00 - Volume
9,984 - Avg. Volume
46,552 - Market Cap (intraday)
94.181M - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-3.52 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
www.enlivex.comRecent News: ENLV.TA
View MorePerformance Overview: ENLV.TA
Trailing total returns as of 12/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENLV.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENLV.TA
View MoreValuation Measures
Market Cap
95.30M
Enterprise Value
10.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.05
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.46%
Return on Equity (ttm)
-61.17%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-22.29M
Diluted EPS (ttm)
-3.52
Balance Sheet and Cash Flow
Total Cash (mrq)
25.94M
Total Debt/Equity (mrq)
2.92%
Levered Free Cash Flow (ttm)
-11.98M